Gefitinib plus interleukin-2 in advanced non-small cell lung cancer patients previously treated with chemotherapy

Cancers

Volumn 6, Issue 4, 2014, Pages 2035-2048

  Bersanelli, Melissa ^a   Buti, Sebastiano ^a   Camisa, Roberta ^a   Brighenti, Matteo ^b   Lazzarelli, Silvia ^b   Mazza, Giancarlo ^c   Passalacqua, Rodolfo ^b  

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

^b CREMONA HOSPITAL   (Italy)

^c SPEDALI CIVILI   (Italy)

Author keywords

Gefitinib; IL 2; Immunotherapy; Interleukin 2; Lung cancer; Non small cell lung cancer; NSCLC; TKI; Tyrosine kinase inhibitors

Indexed keywords

GEFITINIB; INTERLEUKIN 2;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTHRALGIA; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CHILL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; ERYTHEMA; FATIGUE; FEMALE; FEVER; FOLLOW UP; HUMAN; INJECTION SITE INDURATION; MAJOR CLINICAL STUDY; MALAISE; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PILOT STUDY; RASH; SKIN TOXICITY; SURVIVAL TIME; VERY ELDERLY;

EID: 84907677503     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers6042035     Document Type: Article

References (38)

1. Mok, T.S.; Wu, Y.L.; Thongprasert, S.; Yang, C.H.; Chu, D.T.; Saijo, N.; Sunpaweravong, P.; Han, B.; Margono, B.; Ichinose, Y. et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 2009, 361, 947–957.
2. Kim, E.S.; Hirsh, V.; Mok, T.; Socinski, M.A.; Gervais, R.; Wu, Y.L.; Li, L.Y.; Watkins, C.L.; Sellers, M.V.; Lowe, E.S.; Sun, Y. et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): A randomised phase III trial. Lancet 2008, 372, 1809–1818.
3. Douillard, J.Y.; Shepherd, F.A.; Hirsh, V.; Mok, T.; Socinski, M.A.; Gervais, R.; Liao, M.L.; Bischoff, H.; Reck, M.; Sellers, M.V. et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: Data from the randomized phase III INTEREST trial. J. Clin. Oncol. 2010, 28, 744–752.
4. Thatcher, N.; Chang, A.; Parikh, P.; Rodrigues Pereira, J.; Ciuleanu, T.; von Pawel, J.; Thongprasert, S.; Tan, E.H.; Pemberton, K.; Archer, V. et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa survival evaluation in lung cancer). Lancet 2005, 366, 1527–1537.
5. Mitsudomi, T.; Morita, S.; Yatabe, Y.; Negoro, S.; Okamoto, I.; Tsurutani, J.; Seto, T.; Satouchi, M.; Tada, H.; Hirashima, T. et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol. 2010, 11, 121–128.
6. Maemondo, M.; Inoue, A.; Kobayashi, K.; Sugawara, S.; Oizumi, S.; Isobe, H.; Gemma, A.; Harada, M.; Yoshizawa, H.; Kinoshita, I. et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med. 2010, 362, 2380–2388.
7. Ardizzoni, A.; Bonavia, M.; Viale, M.; Baldini, E.; Mereu, C.; Verna, A.; Ferrini, S.; Cinquegrana, A.; Molinari, S.; Mariani, G.L. Biologic and clinical effects of continuous infusion interleukin-2 in patients with non-small cell lung cancer. Cancer 1994, 73, 1353–1360.
8. Schiller, J.H.; Morgan-Ihrig, C.; Levitt, M.L. Concomitant administration of interleukin-2 plus tumor necrosis factor in advanced non-small cell lung cancer. Am. J. Clin. Oncol. 1995, 18, 47–51.
9. Lissoni, P.; Meregalli, S.; Fossati, V.; Paolorossi, F.; Barni, S.; Tancini, G.; Frigerio, F. A randomized study of immunotherapy with low-dose subcutaneous interleukin-2 plus melatonin vs. chemotherapy with cisplatin and etoposide as first-line therapy for advanced non-small cell lung cancer. Tumori 1994, 80, 464–467.
10. Tester, W.J.; Kim, K.M.; Krigel, R.L.; Bonomi, P.D.; Glick, J.H.; Asbury, R.F.; Kirkwood, J.M.; Blum, R.H.; Schiller, J.H. A randomized Phase II study of interleukin-2 with and without beta-interferon for patients with advanced non-small cell lung cancer: An Eastern Cooperative Oncology Group study (PZ586). Lung Cancer 1999, 25, 199–206.
11. De Vita, F.; Turitto, G.; di Grazia, M.; Frattolillo, A.; Catalano, G. Analysis of interleukin-2/ interleukin-2 receptor system in advanced non-small-cell lung cancer. Tumori 1998, 84, 33–38.
12. Chen, Y.M.; Yang, W.K.; Whang-Peng, J.; Tsai, W.Y.; Hung, Y.M.; Yang, D.M.; Lin, W.C.; Perng, R.P.; Ting, C.C. Restoration of the immunocompetence by IL-2 activation and TCR-CD3 engagement of the in vivo anergized tumor-specific CTL from lung cancer patients. J. Immunother. 1997, 20, 354–364.
13. Brahmer, J.R. Harnessing the immune system for the treatment of non-small-cell lung cancer. J. Clin. Oncol. 2013, 31, 1021–1028.
14. McCarthy, F.; Roshani, R.; Steele, J.; Hagemann, T. Current clinical immunotherapy targets in advanced nonsmall cell lung cancer (NSCLC). J. Leukoc. Biol. 2013, 94, 1201–1206.
15. Reck, M. What future opportunities may immuno-oncology provide for improving the treatment of patients with lung cancer? Ann. Oncol. 2012, 8, 28–34.
16. Shepherd, F.A.; Douillard, J.Y.; Blumenschein, G.R., Jr. Immunotherapy for non-small cell lung cancer: Novel approaches to improve patient outcome. J. Thorac. Oncol. 2011, 6, 1763–1773.
17. Quoix, E. Phase IIB/III of TG4010 immunotherapy in patients with stage IV non-small cell lung cancer (TIME). Available online: http://www.clinicaltrials.gov/ct2/show/NCT01383148? term=NCT01383148&rank=1 (accessed on 18 September 2014).
18. Iwai, K.; Soejima, K.; Kudoh, S.; Umezato, Y.; Kaneko, T.; Yoshimori, K.; Tokuda, H.; Yamaguchi, T.; Mizoo, A.; Setoguchi, Y. et al. Extended survival observed in adoptive activated T lymphocyte immunotherapy for advanced lung cancer: Results of a multicenter historical cohort study. Cancer Immunol. Immunother. 2012, 61, 1781–1790.
19. Gupta, P.; Emdad, L.; Lebedeva, I.V.; Sarkar, D.; Dent, P.; Curiel, D.T.; Settleman, J.; Fisher, P.B. Targeted combinatorial therapy of non-small cell lung carcinoma using a GST-fusion protein of full-length or truncated MDA-7/IL-24 with Tarceva. J. Cell Physiol. 2008, 215, 827–836.
20. Emdad, L.; Lebedeva, I.V.; Su, Z.Z.; Gupta, P.; Sarkar, D.; Settleman, J.; Fisher, P.B. Combinatorial treatment of non-small-cell lung cancers with gefitinib and Ad.mda-7 enhances apoptosis-induction and reverses resistance to a single therapy. J. Cell Physiol. 2007, 210, 549–559.
21. Kanazawa, S.; Muramatsu, M.; Kinoshita, Y.; Yamaguchi, K.; Nomura, S. Gefitinib has the potential of activating cell immunity against malignant cells. J. Clin. Oncol. 2005, 23, 3865–3856.
22. Kanazawa, S.; Yamaguchi, K.; Kinoshita, Y.; Komiyama, Y.; Muramatsu, M.; Nomura, S. Elevation of soluble interleukin-2 receptor in patients with non-small cell lung cancer treated with gefitinib. J. Cancer Res. Clin. Oncol. 2006, 132, 719–725.
23. Umekawa, K.; Kimura, T.; Kudoh, S.; Suzumura, T.; Oka, T.; Nagata, M.; Mitsuoka, S.; Matsuura, K.; Nakai, T.; Yoshimura, N. et al. Plasma RANTES, IL-10, and IL-8 levels in non-small-cell lung cancer patients treated with EGFR-TKIs. BMC Res. Notes 2013, 6, e139.
24. Yamamoto, N.; Honma, M.; Suzuki, H. Off-target serine/threonine kinase 10 inhibition by erlotinib enhances lymphocytic activity leading to severe skin disorders. Mol. Pharmacol. 2011, 80, 466–475.
25. Therasse, P.; Arbuck, S.G.; Eisenhauer, E.A.; Wanders, J.; Kaplan, R.S.; Rubinstein, L.; Verweij, J.; van Glabbeke, M.; van Oosterom, A.T.; Christian, M.C. et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 2000, 92, 205–216.
26. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Available online: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf (accessed on 24 June 2014).
27. Grande, C.; Firvida, J.L.; Navas, V.; Casal, J. Interleukin-2 for the treatment of solid tumors other than melanoma and renal cell carcinoma. Anticancer Drugs 2006, 17, 1–12.
28. Masotti, A.; Morandini, G.; Ortolani, R.; Fumagalli, L. Phase-II randomized study of pre-operative IL-2 administration in operable NSCLC. Lung Cancer 1998, 20, 191–202.
29. Recchia, F.; Saggio, G.; Nuzzo, A.; Biondi, E.; Di Blasio, A.; Cesta, A.; Candeloro, G.; Alesse, E.; Rea, S. Multicenter phase 2 study of interleukin-2 and 13-cis retinoic acid as maintenance therapy in advanced non-small-cell lung cancer. J. Immunother. 2006, 29, 87–94.
30. Mantovani, G.; Madeddu, C.; Gramignano, G.; Lusso, M.R.; Mocci, M.; Massa, E.; Ferreli, L.; Astara, G.; Macciò, A.; Serpe, R. Subcutaneous interleukin-2 in combination with medroxyprogesterone acetate and antioxidants in advanced cancer responders to previous chemotherapy: Phase II study evaluating clinical, quality of life, and laboratory parameters. J. Exp. Ther. Oncol. 2003, 3, 205–219.
31. Yang, S.C.; Owen-Schaub, L.; Grimm, E.A.; Roth, J.A. Induction of lymphokine-activated killer cytotoxicity with interleukin-2 and tumor necrosis factor-alpha against primary lung cancer targets. Cancer Immunol. Immunother. 1989, 29, 193–198.
32. Yang, S.C.; Grimm, E.A.; Parkinson, D.R.; Carinhas, J.; Fry, K.D.; Mendiguren-Rodriguez, A.; Licciardello, J.; Owen-Schaub, L.B.; Hong, W.K.; Roth, J.A. Clinical and immunomodulatory effects of combination immunotherapy with low-dose interleukin 2 and tumor necrosis factor alpha in patients with advanced non-small cell lung cancer: A phase I trial. Cancer Res. 1991, 51, 3669–3676.
33. Valone, F.H.; Gandara, D.R.; Deisseroth, A.B.; Perez, E.A.; Rayner, A.; Aronson, F.R.; Luce, J.; Paradise, C. Interleukin-2, cisplatin, and 5-fluorouracil for patients with non-small cell lung and head/neck carcinomas. J. Immunother. 1991, 10, 207–213.
34. Jansen, R.L.; Slingerland, R.; Goey, S.H.; Franks, C.R.; Bolhuis, R.L.; Stoter, G. Interleukin-2 and interferon-alpha in the treatment of patients with advanced non-small-cell lung cancer. J. Immunother. 1992, 12, 70–73.
35. Lissoni, P.; Tisi, E.; Barni, S.; Ardizzoia, A.; Rovelli, F.; Rescaldani, R.; Ballabio, D.; Benenti, C.; Angeli, M.; Tancini, G. Biological and clinical results of a neuroimmunotherapy with interleukin-2 and the pineal hormone melatonin as a first line treatment in advanced non-small cell lung cancer. Br. J. Cancer 1992, 66, 155–158.
36. Mantovani, G.; Macciò, A.; Mulas, C.; Massa, E.; Madeddu, C.; Mura, L.; Contu, P.; Versace, R. Dose-intense phase II study of weekly cisplatin and epidoxorubicin plus medroxyprogesterone acetate and recombinant interleukin 2 in stage IIIB-IV non-small cell lung cancer. Oncol. Rep. 2002, 9, 661–670.
37. Petrelli, F.; Borgonovo, K.; Cabiddu, M.; Lonati, V.; Barni, S. Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: A literature-based meta-analysis of 24 trials. Lung Cancer 2012, 78, 8–15.
38. Liu, H.B.; Wu, Y.; Lv, T.F.; Yao, Y.W.; Xiao, Y.Y.; Yuan, D.M.; Song, Y. Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: A systematic review and meta-analysis. PLoS One 2013, 8, e55128.